One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension -

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension
Information type: Randomised controlled trials
Source: Diabetes, Obesity and Metabolism
Specialities: Diabetes
Summary
RCT (n=807) found more sustained HbA1c reduction for Gla-300 at 12 months. Lower percentages of patients had ≥1 confirmed (≤3.9 mmol/l) or severe hypoglycaemic event with Gla-300 than Gla-100, while annualised rates of such hypoglycaemic events were similar.
UKMi comment
Insulin glargine U300 (Toujeo®) is a new formulation based on the insulin glargine molecule, but with a reduced redissolution rate following subcutaneous administration, resulting in a flatter and more prolonged pharmacokinetic/dynamic profile than Lantus®.
Related links: